BLACK DIAMOND THERAPEUTICS, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
BLACK DIAMOND THERAPEUTICS, INC. (BDTX) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 12.03 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-05
- BLACK DIAMOND THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 11.96M shares, a 10.36% increase year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 10.84M shares, a 2.37% decline year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 11.10M shares, a 36.41% increase year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 8.14M shares, a 35.17% increase year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 9.42M shares, a 5.96% decline from fiscal 2024.
- BLACK DIAMOND THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 10.01M shares, a 21.89% increase from fiscal 2023.
- BLACK DIAMOND THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 8.22M shares, a 42.63% increase from fiscal 2022.
- BLACK DIAMOND THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 5.76M shares, a 15.45% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 12.03M shares 10-Q · filed 2026-08-05 | |||||||
| 2026-03-31 | 11.96M shares 10-Q · filed 2026-05-07 | |||||||
| 2025-12-31 | 9.42M shares 10-K · filed 2026-03-16 | |||||||
| 2025-09-30 | 9.75M shares 10-Q · filed 2025-11-06 | |||||||
| 2025-06-30 | 9.92M shares 10-Q · filed 2026-08-05 | |||||||
| 2025-03-31 | 10.84M shares 10-Q · filed 2026-05-07 | |||||||
| 2024-12-31 | 10.01M shares 10-K · filed 2026-03-16 | |||||||
| 2024-09-30 | 11.29M shares 10-Q · filed 2025-11-06 | |||||||
| 2024-06-30 | 11.49M shares 10-Q · filed 2025-08-07 | |||||||
| 2024-03-31 | 11.10M shares 10-Q · filed 2025-05-12 | |||||||
| 2023-12-31 | 8.22M shares 10-K · filed 2025-03-06 | |||||||
| 2023-09-30 | 8.43M shares 10-Q · filed 2024-11-05 | |||||||
| 2023-06-30 | 8.39M shares 10-Q · filed 2024-08-06 | |||||||
| 2023-03-31 | 8.14M shares 10-Q · filed 2024-05-09 | |||||||
| 2022-12-31 | 5.76M shares 10-K · filed 2024-03-12 | |||||||
| 2022-09-30 | 6.22M shares 10-Q · filed 2023-11-06 | 5.97M shares 10-Q · filed 2022-11-08 | ||||||
| 2022-06-30 | 6.54M shares 10-Q · filed 2023-08-11 | 6.27M shares 10-Q · filed 2022-08-09 | ||||||
| 2022-03-31 | 6.02M shares 10-Q · filed 2023-05-09 | 6.00M shares 10-Q · filed 2022-05-11 | ||||||
| 2021-12-31 | 4.99M shares 10-K · filed 2023-03-09 | 4.97M shares 10-K · filed 2022-03-17 | ||||||
| 2021-09-30 | 4.99M shares 10-Q · filed 2022-11-08 | |||||||
| 2021-06-30 | 5.27M shares 10-Q · filed 2022-08-09 | |||||||
| 2021-03-31 | 4.88M shares 10-Q · filed 2022-05-11 | |||||||
| 2020-12-31 | 3.82M shares 10-K · filed 2022-03-17 | |||||||
| 2020-09-30 | 3.71M shares 10-Q · filed 2021-11-08 | 3.70M shares 10-Q · filed 2020-11-10 | ||||||
| 2020-06-30 | 3.25M shares 10-Q · filed 2021-08-12 | 3.24M shares 10-Q · filed 2020-08-11 | ||||||
| 2020-03-31 | 3.09M shares 10-Q · filed 2021-05-07 | 3.08M shares 10-Q · filed 2020-05-12 | ||||||
| 2019-12-31 | 23.89M shares 10-K · filed 2021-03-25 | |||||||
| 2019-09-30 | 16.81M shares 10-Q · filed 2020-11-10 | |||||||
| 2019-06-30 | 11.84M shares 10-Q · filed 2020-08-11 | |||||||
| 2019-03-31 | 11.43M shares 10-Q · filed 2020-05-12 | |||||||
| 2018-12-31 | 11.35M shares 10-K · filed 2020-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |